STEVENSVILLE, Md., Jan. 22 /PRNewswire-USNewswire/ -- Vapotherm, the
global leader in High Flow Oxygen Therapy products, announced today that
U.S. patent rights have been validated for an apparatus used in the
delivery tube technology for respiratory tract therapy. Reinforcing
Vapotherm's principal role in the industry, the U.S. Patent No. 7,314,046
B2 has been granted through 2022 and provides Vapotherm the right to
prevent or exclude other companies from making, using, selling, or offering
to sell or import the invention.
The triple lumen design is the vital component for Vapotherm products
as it helps deliver humidified air to the respiratory tract of patients.
Used throughout all Vapotherm products, including the 2000i and the
recently introduced Precision Flow(TM), the apparatus allows Vapotherm to
maintain the conditioned breathing gases to the patient and thus aid with
respiratory tract therapy and treatment.
"Our patient delivery circuit design is unique in the field and
provides Vapotherm with a competitive advantage through the delivery of
optimally conditioned breathing gases all the way to the patient, whereas
conventional approaches can result in significant temperature and humidity
loss," said William Niland, Chairman and Chief Business Development Officer
Vapotherm, Inc. is a privately held manufacturer of respiratory care
devices for hospitals and home care use based in Stevensville, Maryland.
The Company is dedicated to the development of innovative, noninvasive
technologies for respiratory therapy, especially for the treatment of
chronic lung and acute breathing disorders. For more information, visit
Amy Elias/Brian Johnson
SOURCE Vapotherm, Inc.